THE C-ERBB-2 PROTOONCOGENE AS A PROGNOSTIC AND PREDICTIVE MARKER IN BREAST-CANCER - A PARADIGM FOR THE DEVELOPMENT OF OTHER MACROMOLECULAR MARKERS - A REVIEW
THE C-ERBB-2 PROTOONCOGENE AS A PROGNOSTIC AND PREDICTIVE MARKER IN BREAST-CANCER - A PARADIGM FOR THE DEVELOPMENT OF OTHER MACROMOLECULAR MARKERS - A REVIEW
复制标题
DOI：
10.1016/0378-1119(94)00866-q
复制
发表时间：
1995-06-14
期刊：
影响因子：
3.5
通讯作者：
CHAMNESS, GC
中科院分区：
文献类型：
--
作者：
RAVDIN, PM;CHAMNESS, GC
原癌基因 c-erbB-2 在乳腺癌中的预后价值的初步研究七年后，其作用仍在确定中。由于多种方法和研究中固有的困难，对该基因及其蛋白质产物在乳腺癌预后和预测测试中的应用的研究的解释变得复杂。这项工作已经超越了短期随访（对假设生成有用）的小型研究具有价值的阶段，进入了以具有足够统计能力来发现显着相关性的大型研究为中心的阶段。这些更大规模的研究并不支持使用 c-erbB-2 来评估腋窝淋巴结阴性患者，对于这类乳腺癌患者来说，完善预后估计现在是最重要的。然而，有迹象表明，c-erbB-2 在预测对某些治疗的反应方面可能具有价值，尽管迄今为止的研究太少、往往太小且相互矛盾，无法可靠地证实这一点。
Seven years after the initial studies of the prognostic value of the proto-oncogene c-erbB-2 in breast cancer, its role is still being defined. The interpretation of studies on the use of this gene and its protein product in prognostic and predictive tests for breast cancer is complicated by multiple methodologies and the inherent difficulties in the studies. The work has moved beyond the stage at which small studies with short follow-up (useful for hypothesis generation) are of value, to the stage in which large studies with sufficient statistical power to find significant correlations are central. These larger studies do not lend support for the use of c-erbB-2 in the evaluation of axillary-node-negative patients, the group of breast cancer patients for whom refinement of prognostic estimates is now most important. There are, however, hints that c-erbB-2 may have value in predicting response to certain treatments, though the studies so far are too few, often too small and too conflicting to reliably confirm this.